12 research outputs found
Clinical highlights from the 2016 European Respiratory Society International Congress
This article contains highlights and a selection of the scientific advances from the European Respiratory Society (ERS) Clinical Assembly (Assembly 1) and its six respective groups (Groups 1.1–1.6) that were presented at the 2016 ERS International Congress in London, UK. The most relevant topics for clinicians will be discussed, covering a wide range of areas including clinical problems, rehabilitation and chronic care, thoracic imaging, interventional pulmonology, diffuse and parenchymal lung diseases, and general practice and primary care. In this comprehensive review, the newest research and actual data will be discussed and put into perspective
Post-COVID-19 interstitial lung disease: Insights from a machine learning radiographic model
IntroductionPost-acute sequelae of COVID-19 seem to be an emerging global crisis. Machine learning radiographic models have great potential for meticulous evaluation of post-COVID-19 interstitial lung disease (ILD).MethodsIn this multicenter, retrospective study, we included consecutive patients that had been evaluated 3 months following severe acute respiratory syndrome coronavirus 2 infection between 01/02/2021 and 12/5/2022. High-resolution computed tomography was evaluated through Imbio Lung Texture Analysis 2.1.ResultsTwo hundred thirty-two (n = 232) patients were analyzed. FVC% predicted was ≥80, between 60 and 79 and <60 in 74.2% (n = 172), 21.1% (n = 49), and 4.7% (n = 11) of the cohort, respectively. DLCO% predicted was ≥80, between 60 and 79 and <60 in 69.4% (n = 161), 15.5% (n = 36), and 15.1% (n = 35), respectively. Extent of ground glass opacities was ≥30% in 4.3% of patients (n = 10), between 5 and 29% in 48.7% of patients (n = 113) and <5% in 47.0% of patients (n = 109). The extent of reticulation was ≥30%, 5–29% and <5% in 1.3% (n = 3), 24.1% (n = 56), and 74.6% (n = 173) of the cohort, respectively. Patients (n = 13, 5.6%) with fibrotic lung disease and persistent functional impairment at the 6-month follow-up received antifibrotics and presented with an absolute change of +10.3 (p = 0.01) and +14.6 (p = 0.01) in FVC% predicted at 3 and 6 months after the initiation of antifibrotic.ConclusionPost-COVID-19-ILD represents an emerging entity. A substantial minority of patients presents with fibrotic lung disease and might experience benefit from antifibrotic initiation at the time point that fibrotic-like changes are “immature.” Machine learning radiographic models could be of major significance for accurate radiographic evaluation and subsequently for the guidance of therapeutic approaches
Nasal high-flow oxygen versus noninvasive ventilation in acute exacerbation of COPD: protocol for a randomised noninferiority clinical trial
Background: Noninvasive ventilation (NIV) is considered as the
first-line treatment for acute exacerbation of COPD (AECOPD) complicated
by respiratory acidosis. Recent studies demonstrate a role of nasal
high-flow oxygen (NHF) in AECOPD as an alternative treatment in patients
intolerant to NIV or with contraindications to it.
Aim: The study aimed to evaluate whether NHF respiratory support is
noninferior compared to NIV in respect to treatment failure, defined as
need for intubation or change to alternative treatment group, in
patients with AECOPD and mild-to-moderate acute or acute-on-chronic
hypercapnic respiratory failure.
Methods: We designed a multicentre, prospective, randomised trial on
patients with AECOPD, who have pH<7.35 but >7.25 and P-aCO2 >45 mmHg, in
whom NIV is indicated as a first-line treatment. According to power
analysis, 498 participants will be required for establishing
noninferiority of NHF compared to NIV. Patients will be randomly
assigned to receive NIV or NHF. Treatment will be adjusted to maintain
S-pO2 between 88%-92% for both groups. Arterial blood gases,
respiratory variables, comfort, dyspnoea score and any pulmonary or
extrapulmonary complications will be assessed at baseline, before
treatment initiation, and at 1, 2, 4, 6, 12, 24, 48 h, then once daily
from day 3 to patient discharge, intubation or death.
Conclusion: Given the increasing number of studies demonstrating the
physiological effects of NHF in COPD patients, we hypothesise that NHF
respiratory support will be noninferior to NIV in patients with AECOPD
and mild-to-moderate acute or acute on chronic hypercapnic respiratory
failure
Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis
Abstract Background Increased protein citrullination and peptidylarginine deiminases (PADIs), which catalyze the citrullination process, are central in Rheumatoid arthritis pathogenesis and probably involved in the initial steps towards autoimmunity. Approximately, 10% of RA patients develop clinically significantly ILD. A possible shared role of protein citrullination in rheumatoid arthritis associated interstitial lung disease (RA-ILD), and idiopathic pulmonary fibrosis (IPF) pathogenesis remains unclear. Methods We evaluated PADI2 and PADI4 mRNA expression in bronchoalveolar lavage fluid (BALF) cells of 59 patients with IPF, 27 patients RA-ILD and 10 healthy controls. PADI 2 and 4 expression was analyzed by western blot and immunohistochemistry. Citrullinated protein levels were also quantified. Results PADI4 mRNA and protein levels were higher in RA-ILD and IPF than controls. Furthermore, PADI4 mRNA levels showed an increase among smokers in RA-ILD. PADI4 expression was detected in granulocytes and macrophages in all groups, with the strongest cytoplasmic expression observed in granulocytes in RA-ILD and IPF. PADI2 mRNA and immunostaining of BAL cells, were similar in all groups among smokers. Overall, stronger staining was observed in current smokers. Citrullinated peptides were significantly increased in IPF compared to RA-ILD and controls. In RA-ILD, protein citrullination strongly correlated with PADI4 expression and anti-citrullinated protein antibodies (ACPAs). Conclusions These results suggest that the citrullination pathway is upregulated in IPF and in RA-ILD
Pirfenidone improves survival in IPF: results from a real-life study
Abstract Background Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the restrictions of a clinical trial. Methods This is a retrospective observational intention to treat study of 82 consecutive IPF patients (UHH cohort). Results We observed a high 3-years survival rate of 73% without excluding patients who discontinued treatment for different reasons. The survival was compared to the survival of an IPF cohort from a tertiary referral center (RBH cohort). After exclusion of severe cases (DLco< 30%), in unadjusted analysis, the survival in the UHH cohort was better than in the RBH cohort (HR:0.32, 95% CI: 0.19–0.53, p < 0.0001). After adjustment for age, gender and FVC, the survival remained higher in the UHH cohort (HR:0.28, 95% CI: 0.16–0.48, p < 0.0001). We observed a similar safety profile compared to previously published data and a lower rate of drug discontinuation due to photosensitivity reactions. Conclusion: Pirfenidone provides a survival benefit in a real-life IPF cohort compared to previously used medications. Counselling patients and proactively managing possible adverse effects can reduce the necessity to discontinue pirfenidone
Additional file 1: Figure S1. of Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis
A representative immunoblot of PADI2 in three (3) control, six (6) IPF and six (6) RA-ILD subjects. PADI2 protein correspond to the 72kDA band observed. (DOCX 11Â kb